Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > LATEST
LATEST
-
ORGANIZATION JPMA Think Tank Chief Pledges to Back Policy Debates with Evidence
September 26, 2025
-
REGULATORY Pharma Support Needed to Bridge Biotech’s “Valley of Death”: Council Member
September 26, 2025
-
REGULATORY Cost-Effectiveness Talks Continue on Expanding HPV Vaccinations to Males
September 26, 2025
-
BUSINESS Fujifilm Launches US$3.2 Billion Biologics Plant in North Carolina
September 26, 2025
-
BUSINESS MEDRx/DWTI Clinch US FDA Approval for Lidocaine Patch
September 26, 2025
-
ORGANIZATION Japanese Pharma-Cosmetic Union Breaks from UA Zensen, Set to Join Rengo
September 25, 2025
-
ORGANIZATION JPMA to Overhaul Guideline for Handling Drug Inquiries This Fall: Consultation Chair
September 25, 2025
-
BUSINESS Nippon Zoki Shooting for 50% Overseas Sales by FY2035
September 25, 2025
-
BUSINESS Australia Clears Leqembi after Tribunal Review
September 25, 2025
-
BUSINESS Taiho Hooks Up with Guardant Health in Biomarker Search
September 25, 2025
-
BUSINESS GE HealthCare to Develop Lantheus’ Prostate Cancer PET Agent in Japan
September 25, 2025
-
ORGANIZATION Generic Use Rate at 89.6% in April: Payer
September 25, 2025
-
BUSINESS Eisai Settles US Lenvima Suit with Dr. Reddy’s, Generic Launch Barred Until 2030
September 25, 2025
-
BUSINESS Enhertu Combo Accepted for US Review in First-Line HER2 Breast Cancer
September 25, 2025
-
BUSINESS Chugai Seeks Avastin Label Expansion for Neurofibromatosis Type 2
September 25, 2025
-
REGULATORY LDP Leadership Race Underway, Healthcare-Savvy Lawmakers Among Endorsers
September 24, 2025
-
BUSINESS Mochida and Itochu to Each Take 20% Stake in And Pharma
September 24, 2025
-
REGULATORY FPMAJ Calls for Scrapping Huge-Seller, Spillover Re-Pricing at Public-Private WG Hearing
September 24, 2025
-
BUSINESS PharmaEssentia Files for ET Indication of Besremi in Japan
September 24, 2025
-
BUSINESS FDA Turns Down Otsuka’s PTSD Bid for Rexulti
September 24, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…